Financials

Discussions Technicals Seasonals

308080 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

‪62.80 B‬KRW

—

—

−731.86KRW

2013

—

Tae Gyu Kim

vigencell.co.kr

About

ViGenCell, Inc. engages in the research and development of pharmaceutical and immune cell therapy products. Its products pipeline includes ViTier, ViMedier, and ViRanger. The company was founded on February 1, 2013 and is headquartered in Seoul, South Korea.

Ownership

‪‪19.26 M‬‬

Free Float shares

‪‪12.80 M‬‬ (66.47%)

Closely held shares

‪‪6.46 M‬‬ (33.53%)

Free Float shares

‪‪12.80 M‬‬ (66.47%)

Closely held shares

‪‪6.46 M‬‬ (33.53%)

Capital structure

Market cap

‪‪62.80 B‬‬

Enterprise value

‪‪62.80 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary

‪‪62.80 B‬‬

Price to earning ratio (P/E)

—

Price to sales ratio (P/S)

—

Market Cap

Net income

Revenue

Price to earning ratio (P/E)

—

Price to sales ratio (P/S)

—

Valuation ratios

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q4 '24

‪0.00‬

‪350.00‬

‪700.00‬

‪‪1.05 K‬‬

‪‪1.40 K‬‬

P/S

Growth and Profitability

Company’s recent performance and margins

Performance

‪−681,500.0%‬

‪−511,500.0%‬

‪−341,500.0%‬

‪−171,500.0%‬

‪−1,500.0%‬

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q4 '24

‪‪−5.10 B‬‬

‪‪−3.40 B‬‬

‪‪−1.70 B‬‬

‪0.00‬

‪‪1.70 B‬‬

Revenue

Net income

Net margin %

Revenue to profit conversion

Revenue

COGS

Gross profit

Op expenses

Op income

Non-Op income/ expenses

Taxes & Other

Net income

‪‪−4.50 B‬‬

‪‪−3.00 B‬‬

‪‪−1.50 B‬‬

‪0.00‬

‪‪1.50 B‬‬

Revenue

COGS

Gross profit

Expenses & adjustments

Net income

‪‪−4.50 B‬‬

‪‪−3.00 B‬‬

‪‪−1.50 B‬‬

‪0.00‬

‪‪1.50 B‬‬

Dividends

Dividend yield, history and sustainability

308080 does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q4 '24

‪‪−7.00 B‬‬

‪0.00‬

‪‪7.00 B‬‬

‪‪14.00 B‬‬

‪‪21.00 B‬‬

Debt

Free cash flow

Cash & equivalents

Financial position analysis

No data available

There's currently no assets and liabilities data to show.